230 Studies Now Enrolling
Menu
Search
Status
Medical Condition
Displaying 1 - 5 of 5
Condition: Psychiatric Disorders / Depression
Investigator: David Hellerstein, MD
Status: Closed
We are currently enrolling individuals with Major Depressive Disorder (MDD) to participate in this research study. This is a one-year open-label study to evaluate the long-term safety and tolerability of an investigational drug called REL-1017 (esmethadone) when taken alone (monotherapy) or when taken with other antidepressants (adjunctive therapy). Study…
Condition: Psychiatric Disorders / Depression
Investigator: Patrick Brown, PhD
Status: Closed
We are studying the relationship between mitochondrial function and the experience of fatigue. Mitochondria are the powerhouses of the cell. Cells within different organs contain hundreds to thousands of mitochondria, which sustain life and fuel energy-dependent processes that we do every day including muscle contraction and cognitive activity. They act…
Condition: Psychiatric Disorders / Depression
Investigator: Elizabeth Sublette, MD, PhD
Status: Closed
This research study uses non-invasive brain imaging called functional near-infrared spectroscopy (fNIRS). For fNIRS, a small infrared bulb shines light through the skull, and a special light detector is able to measure oxygen use in the brain. Our goal is to understand oxygen use by brain mitochondria cells in major depression and how this is affected by…
Condition: Blood Disorders / Amyloidosis
Investigator: Thomas Brannagan, MD
Status: Closed
HELIOS-A is a global Phase 3 randomized, open-label study designed to evaluate the safety and efficacy of ALN-TTRSC02 in adult patients with hATTR amyloidosis experiencing neurologic symptoms brought on by the disease. The study will also evaluate any changes in quality of life experienced by study participants. ALN-TTRSC02 utilizes the mechanism of RNA…
Condition: Blood Disorders / Amyloidosis
Investigator: Thomas Brannagan, MD
Status: Closed
The purpose of this study is to evaluate the efficacy and safety of ION-682884 given for 24 months in patients with hereditary transthyretin-mediated amyloid polyneuropathy (hATTR-PN) also known as Familial Amyloid Polyneuropathy (FAP), and determine if it can help people with mild or moderate polyneuropathy. To be in this study you must have FAP and be…